Trexquant Investment LP Takes $6.04 Million Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Trexquant Investment LP bought a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 175,574 shares of the company's stock, valued at approximately $6,042,000. Trexquant Investment LP owned about 0.31% of Harmony Biosciences at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Harmony Biosciences by 36.4% during the 4th quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock worth $162,883,000 after buying an additional 1,262,362 shares in the last quarter. Pacer Advisors Inc. increased its position in shares of Harmony Biosciences by 18.2% during the fourth quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock valued at $78,452,000 after acquiring an additional 351,582 shares during the last quarter. American Century Companies Inc. lifted its holdings in Harmony Biosciences by 28.7% during the fourth quarter. American Century Companies Inc. now owns 1,102,604 shares of the company's stock worth $37,941,000 after acquiring an additional 246,140 shares during the period. Geode Capital Management LLC boosted its position in Harmony Biosciences by 22.8% in the fourth quarter. Geode Capital Management LLC now owns 902,934 shares of the company's stock worth $31,077,000 after purchasing an additional 167,516 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Harmony Biosciences by 27.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 472,028 shares of the company's stock valued at $16,242,000 after purchasing an additional 100,586 shares during the period. 86.23% of the stock is owned by institutional investors.

Insider Buying and Selling at Harmony Biosciences

In other Harmony Biosciences news, CFO Sandip Kapadia sold 1,775 shares of Harmony Biosciences stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $38.05, for a total transaction of $67,538.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jeffrey Dierks sold 10,507 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $37.01, for a total transaction of $388,864.07. The disclosure for this sale can be found here. Insiders sold a total of 72,452 shares of company stock valued at $2,831,679 in the last three months. Company insiders own 30.80% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on HRMY shares. Mizuho boosted their price target on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a report on Tuesday, March 18th. Needham & Company LLC reiterated a "buy" rating and issued a $50.00 target price on shares of Harmony Biosciences in a research note on Tuesday. HC Wainwright restated a "buy" rating and set a $70.00 price target on shares of Harmony Biosciences in a research note on Tuesday. Finally, Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price objective on the stock. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $53.33.

Harmony Biosciences Stock Performance

Shares of Harmony Biosciences stock traded down $1.02 during trading hours on Thursday, reaching $28.05. The company had a trading volume of 252,946 shares, compared to its average volume of 562,869. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. Harmony Biosciences Holdings, Inc. has a one year low of $26.47 and a one year high of $41.61. The firm has a market cap of $1.61 billion, a PE ratio of 13.23, a price-to-earnings-growth ratio of 0.47 and a beta of 0.80. The business has a fifty day simple moving average of $34.28 and a 200 day simple moving average of $34.92.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.11. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business had revenue of $201.30 million during the quarter, compared to analyst estimates of $201.25 million. During the same quarter in the previous year, the firm earned $0.45 EPS. The company's quarterly revenue was up 19.5% compared to the same quarter last year. On average, analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.